<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04473911</url>
  </required_header>
  <id_info>
    <org_study_id>19-336</org_study_id>
    <nct_id>NCT04473911</nct_id>
  </id_info>
  <brief_title>Haplo Peripheral Blood Sct In GVHD Prevention</brief_title>
  <official_title>Reduced Intensity Haploidentical Peripheral Blood Stem Cell Transplantation With Post-transplant Cyclophosphamide and Sirolimus/Mycophenolate Mofetil/RGI-2001 Based GVHD Prevention: a Pilot Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Zachariah Michael DeFilipp</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Regimmune Corporation</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Massachusetts General Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This research study is studying the RGI-2001 for preventing Graft-vs-Host Disease (GVHD) in&#xD;
      people with acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL), myelodysplastic&#xD;
      syndrome (MDS), myeloproliferative disorders (MPN), chronic myelomonocytic leukemic (CMML),&#xD;
      chemosensitive hodgkin lymphoma (HL), or Non-Hodgkin lymphoma (NHL).who will have a blood&#xD;
      stem cell transplantation.&#xD;
&#xD;
        -  GVHD is a condition in which cells from the donor's tissue attack the organs.&#xD;
&#xD;
        -  RGI-2001 is an investigational treatment&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      -  This is a pilot study in subjects undergoing reduced-intensity haploidentical peripheral&#xD;
           blood stem cell transplantation who will receive graft-versus-host disease prevention&#xD;
           with post-transplant cyclophosphamide, followed by sirolimus, mycophenolate mofetil, and&#xD;
           RGI-2001.&#xD;
&#xD;
        -  The research study procedures include screening for eligibility and study treatment&#xD;
           including evaluations and follow up visits.&#xD;
&#xD;
        -  The standard of care drugs of fludarabine, cyclophosphamide, melphalan, radiation,&#xD;
           sirolimus, and mycophenolate mofetil are all FDA approved.&#xD;
&#xD;
             -  Eligible Participants will be placed in 1 of 2 groups, per physicians discretion:&#xD;
&#xD;
             -  Regimen #1 :&#xD;
&#xD;
                  -  Before stem cell transplant:Fludarabine + Cyclophosphamide + Radiation&#xD;
&#xD;
                  -  After stem cell transplant: Cyclophosphamide + Sirolimus +Mycophenolate&#xD;
                     mofetil + RGI-2001&#xD;
&#xD;
             -  Regimen #2&#xD;
&#xD;
                  -  Before stem cell transplant: fludarabine + melphalan + radiation&#xD;
&#xD;
                  -  After stem cell transplant: cyclophosphamide + sirolimus +Mycophenolate&#xD;
                     mofetil + RGI-2001&#xD;
&#xD;
        -  A total of 20 participants will be enrolled to this trial&#xD;
&#xD;
        -  The U.S. Food and Drug Administration (FDA) has not approved RGI-2001 as a treatment for&#xD;
           any disease.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 14, 2020</start_date>
  <completion_date type="Anticipated">December 2023</completion_date>
  <primary_completion_date type="Anticipated">December 2022</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of patients achieving successful donor engraftment</measure>
    <time_frame>60 Days</time_frame>
    <description>(absolute neutrophil count &gt; 500/uL and ≥ 90% donor cell chimerism)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>100-day non-relapse mortality (NRM) rate.</measure>
    <time_frame>100 Days</time_frame>
    <description>The regimen will be considered as safe if 100d NRM rate is &lt;=5%, and not safe if 100d NRM rate is ≥25%.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>GVHD</condition>
  <condition>AML</condition>
  <condition>ALL</condition>
  <condition>MDS</condition>
  <condition>MPN</condition>
  <condition>CMML</condition>
  <condition>Hodgkin Lymphoma</condition>
  <condition>Non Hodgkin Lymphoma</condition>
  <condition>Blood Stem Cell Transplant Failure</condition>
  <condition>Graft Vs Host Disease</condition>
  <condition>Acute Myeloid Leukemia</condition>
  <condition>Acute Lymphoblastic Leukemia</condition>
  <condition>Myelodysplastic Syndromes</condition>
  <condition>Myeloproliferative Disorder</condition>
  <condition>Chronic Myelomonocytic Leukemia</condition>
  <condition>Chemosensitive Hodgkin Lymphoma</condition>
  <arm_group>
    <arm_group_label>Regimen 1: Fludarabine, Cyclophosphamide, and TBI</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>-. Patients who meet eligibility criteria for the study will subsequently be enrolled for treatment. Two reduced intensity regimens will be allowed, according to the choice of the treating physician&#xD;
Pre- stem cell transplant:&#xD;
Fludarabine predetermined dose, intravenously, 4 times per cycle&#xD;
Cyclophosphamide predetermined dose, predetermined number of times in cycle, intravenous infusion&#xD;
Total body irradiation (TBI) once during treatment cycle&#xD;
Post stem cell transplant:&#xD;
Cyclophosphamide predetermined dose, predetermined number of times in cycle, intravenous infusion&#xD;
Sirolimus: Predetermined dosage, predetermined number of time in cycle, oral.&#xD;
Mycophenolate mofetil, oral or iv(predetermined dose or IV TID (based upon actual body weight), at predetermined times per cycle&#xD;
RGI-2001: IV, predetermined dose, weekly to 6 total doses</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Regimen 2: Fludarabine, Melphalan, and TBI</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>-. Patients who meet eligibility criteria for the study will subsequently be enrolled for treatment. Two reduced intensity regimens will be allowed, according to the choice of the treating physician&#xD;
Pre- stem cell transplant:&#xD;
Fludarabine predetermined dose, intravenously 3 times per cycle&#xD;
Melphalan, infusion, determined dosage, once per cycle&#xD;
Total body irradiation (TBI) once per cycle.&#xD;
Post stem cell transplant&#xD;
Cyclophosphamide predetermined dose, predetermined number of times in cycle, intravenous infusion&#xD;
Sirolimus: Predetermined dosage, predetermined number of time in cycle, oral:&#xD;
Mycophenolate mofetil, oral or iv(predetermined dose or IV TID (based upon actual body weight), at predetermined times per cycle&#xD;
RGI-2001: IV, predetermined dose, weekly to 6 total doses</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>FLUDARABINE</intervention_name>
    <description>predetermined dose, intravenously, a predetermined times per cycle Given in both pre stem cell and post stem cell cycles</description>
    <arm_group_label>Regimen 1: Fludarabine, Cyclophosphamide, and TBI</arm_group_label>
    <arm_group_label>Regimen 2: Fludarabine, Melphalan, and TBI</arm_group_label>
    <other_name>Fludara®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CYCLOPHOSPHAMIDE</intervention_name>
    <description>◦Cyclophosphamide predetermined dose, predetermined number of times in Given in pre-stem cell Regimen #1 Cyclophosphamide predetermined dose, predetermined number of times in cycle, intravenous infusion</description>
    <arm_group_label>Regimen 1: Fludarabine, Cyclophosphamide, and TBI</arm_group_label>
    <other_name>Cytoxan®</other_name>
    <other_name>Neosar®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>TBI</intervention_name>
    <description>Total body irradiation (TBI) once per cycle.</description>
    <arm_group_label>Regimen 1: Fludarabine, Cyclophosphamide, and TBI</arm_group_label>
    <arm_group_label>Regimen 2: Fludarabine, Melphalan, and TBI</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Melphalan</intervention_name>
    <description>Melphalan, infusion, determined dosage, once per cycle</description>
    <arm_group_label>Regimen 2: Fludarabine, Melphalan, and TBI</arm_group_label>
    <other_name>Alkeran®</other_name>
    <other_name>L-PAM</other_name>
    <other_name>L-Sarcolysin</other_name>
    <other_name>Phenylalanine Mustard</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sirolimus</intervention_name>
    <description>Sirolimus: Predetermined dosage, predetermined number of time in cycle, oral: Please note that doses of sirolimus can be adjusted at the treating physician's discretion given the multiple drugs and other situations which affect its metabolism</description>
    <arm_group_label>Regimen 1: Fludarabine, Cyclophosphamide, and TBI</arm_group_label>
    <arm_group_label>Regimen 2: Fludarabine, Melphalan, and TBI</arm_group_label>
    <other_name>Rapamune</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Mycophenolate mofetil</intervention_name>
    <description>◦Mycophenolate mofetil, oral or iv(predetermined dose or IV TID (based upon actual body weight), at predetermined times per cycle</description>
    <arm_group_label>Regimen 1: Fludarabine, Cyclophosphamide, and TBI</arm_group_label>
    <arm_group_label>Regimen 2: Fludarabine, Melphalan, and TBI</arm_group_label>
    <other_name>CellCept</other_name>
    <other_name>Myfortic</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>RGI-2001</intervention_name>
    <description>IV, predetermined dose, weekly to 6 total doses</description>
    <arm_group_label>Regimen 1: Fludarabine, Cyclophosphamide, and TBI</arm_group_label>
    <arm_group_label>Regimen 2: Fludarabine, Melphalan, and TBI</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CYCLOPHOSPHAMIDE</intervention_name>
    <description>◦Given in Post Stem Cell cycle of Regimen #1 and #2 Cyclophosphamide predetermined dose, predetermined number of times in cycle, intravenous infusion</description>
    <arm_group_label>Regimen 1: Fludarabine, Cyclophosphamide, and TBI</arm_group_label>
    <arm_group_label>Regimen 2: Fludarabine, Melphalan, and TBI</arm_group_label>
    <other_name>Cytoxan®</other_name>
    <other_name>Neosar®</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Men or women ≥ 18 and ≤ 80 years old&#xD;
&#xD;
          -  Diagnosis of hematological malignancy:&#xD;
&#xD;
               -  Acute myeloid leukemia (AML) or acute lymphoblastic leukemia (ALL) in morphologic&#xD;
                  complete remission&#xD;
&#xD;
               -  Myelodysplastic syndrome (MDS), myeloproliferative disorders (MPN), or chronic&#xD;
                  myelomonocytic leukemic (CMML) with &lt; 5% blasts in blood or bone marrow&#xD;
&#xD;
               -  Chemosensitive Hodgkin lymphoma (HL) or Non-Hodgkin lymphoma (NHL)&#xD;
&#xD;
          -  Patients must be undergoing haploidentical allogeneic hematopoietic cell&#xD;
             transplantation, defined as 1st or 2nd degree relative with at least 5/10 matching at&#xD;
             HLA-A, -B, -C, DR, and DQ.&#xD;
&#xD;
          -  ECOG performance status ≤2&#xD;
&#xD;
          -  Patients with adequate physical function as measured by:&#xD;
&#xD;
               -  Cardiac: Left ventricular ejection fraction at rest must be ≥ 40%, or shortening&#xD;
                  fraction &gt;25%&#xD;
&#xD;
               -  Hepatic:&#xD;
&#xD;
                    -  Bilirubin ≤ 2.5 mg/dL, except for patients with Gilbert's syndrome or&#xD;
                       hemolysis&#xD;
&#xD;
                    -  ALT, AST, and Alkaline Phosphatase &lt; 5 x ULN&#xD;
&#xD;
               -  Renal: Serum creatinine within normal range, or if serum creatinine is outside&#xD;
                  normal range, then renal function (measured or estimated creatinine clearance or&#xD;
                  GFR) ≥ 40mL/min/1.73m2&#xD;
&#xD;
               -  Pulmonary: DLCO (corrected for hemoglobin), FEV1 and FVC ≥ 50% predicted&#xD;
&#xD;
          -  Ability to understand and the willingness to sign a written informed consent document&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Prior allogeneic hematopoietic stem cell transplantation. (Patients may have received&#xD;
             a prior autologous hematopoietic stem cell transplant.)&#xD;
&#xD;
          -  Participants who are receiving any other investigational agents within 14 days prior&#xD;
             to RGI-2001 dosing. Thus, participants must stop investigational agents by Day -9&#xD;
             prior to transplant.&#xD;
&#xD;
          -  Uncontrolled intercurrent illness including, but not limited to, symptomatic&#xD;
             congestive heart failure, recent myocardial infarction or stroke, unstable angina&#xD;
             pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would&#xD;
             limit compliance with study requirements.&#xD;
&#xD;
          -  Patients with active or uncontrolled bacterial, viral, or fungal infection(s)&#xD;
             requiring systemic therapy.&#xD;
&#xD;
          -  Planned use of prophylactic donor lymphocyte infusion (DLI) therapy.&#xD;
&#xD;
          -  Pregnant and breast-feeding women are ineligible because they are not eligible for&#xD;
             hematopoietic stem cell transplantation.&#xD;
&#xD;
          -  HIV-positive participants and patients with active Hepatitis B or C are ineligible&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Zachariah DeFilipp, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Massachusetts General Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Zachariah DeFilipp, MD</last_name>
    <phone>(617) 726-5765</phone>
    <email>zdefilipp@mgh.harvard.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>Massachusetts General Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Zachariah DeFilipp, MD</last_name>
      <phone>617-726-5765</phone>
    </contact>
    <investigator>
      <last_name>Zachariah DeFilipp, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>July 13, 2020</study_first_submitted>
  <study_first_submitted_qc>July 13, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">July 16, 2020</study_first_posted>
  <last_update_submitted>September 30, 2021</last_update_submitted>
  <last_update_submitted_qc>September 30, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 4, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Massachusetts General Hospital</investigator_affiliation>
    <investigator_full_name>Zachariah Michael DeFilipp</investigator_full_name>
    <investigator_title>Sponsor Investigator</investigator_title>
  </responsible_party>
  <keyword>GVHD</keyword>
  <keyword>AML</keyword>
  <keyword>ALL</keyword>
  <keyword>MDS</keyword>
  <keyword>MPN</keyword>
  <keyword>CMML</keyword>
  <keyword>Hodgkin Lymphoma</keyword>
  <keyword>Non Hodgkin Lymphoma</keyword>
  <keyword>Blood Stem Cell Transplant Failure</keyword>
  <keyword>Graft Vs Host Disease</keyword>
  <keyword>Acute Myeloid Leukemia</keyword>
  <keyword>Acute Lymphoblastic Leukemia</keyword>
  <keyword>Myelodysplastic Syndromes</keyword>
  <keyword>Myeloproliferative Disorder</keyword>
  <keyword>Chronic Myelomonocytic Leukemia</keyword>
  <keyword>Chemosensitive Hodgkin Lymphoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Myeloid</mesh_term>
    <mesh_term>Leukemia, Myeloid, Acute</mesh_term>
    <mesh_term>Preleukemia</mesh_term>
    <mesh_term>Lymphoma, Non-Hodgkin</mesh_term>
    <mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
    <mesh_term>Leukemia, Lymphoid</mesh_term>
    <mesh_term>Hodgkin Disease</mesh_term>
    <mesh_term>Leukemia, Myelomonocytic, Chronic</mesh_term>
    <mesh_term>Leukemia, Myelomonocytic, Juvenile</mesh_term>
    <mesh_term>Myelodysplastic Syndromes</mesh_term>
    <mesh_term>Myeloproliferative Disorders</mesh_term>
    <mesh_term>Graft vs Host Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Mycophenolic Acid</mesh_term>
    <mesh_term>Sirolimus</mesh_term>
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Melphalan</mesh_term>
    <mesh_term>Fludarabine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>The Dana-Farber / Harvard Cancer Center encourages and supports the responsible and ethical sharing of data from clinical trials. De-identified participant data from the final research dataset used in the published manuscript may only be shared under the terms of a Data Use Agreement. Requests may be directed to, please contact the Sponsor Investigator or designee]. The protocol and statistical analysis plan will be made available on Clinicaltrials.gov only as required by federal regulation or as a condition of awards and agreements supporting the research.</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Informed Consent Form (ICF)</ipd_info_type>
    <ipd_time_frame>Data can be shared no earlier than 1 year following the date of publication</ipd_time_frame>
    <ipd_access_criteria>Contact the Partners Innovations team at http://www.partners.org/innovation</ipd_access_criteria>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

